{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:04:18Z","timestamp":1760295858025,"version":"3.37.3"},"reference-count":21,"publisher":"Bentham Science Publishers Ltd.","issue":"9","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81502315"],"award-info":[{"award-number":["81502315"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2019,12,20]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Malignant pheochromocytoma (mPCC) is an uncommon tumor with poor\nprognosis, and no effective therapeutic strategy exists as yet. Discovering new and effective therapeutic\nstrategies to improve prognosis is an urgent need.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To investigate whether a combinatorial inhibition of both mTORC2 and Hsp90 in PC12\ncells could lead to a distinct anti-tumor effect in vitro and in vivo that was greater than the inhibition\nof mTORC2 or Hsp90 alone.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Targeting mTORC2 was assessed by knockdown of Rictor using shRNA, and 17-AAG\nwas used to inhibit Hsp90 function.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Combinatorial inhibition of both mTORC2 and Hsp90 could lead to a distinct anti-tumor\neffect in vitro that was greater than the inhibition of mTORC2 or Hsp90 alone. Inhibiting Hsp90\nspecifically could inhibit tumor growth of sh-Rictor cells in vivo, suggesting that the combinatorial\ninhibition of both mTORC2 and Hsp90 could lead to a distinct anti-tumor effect in vivo. Western\nblotting has shown that both p-Akt Ser473 and p-Akt Thr450 showed significantly decreased expression\nafter targeting mTORC2, while p-Akt Thr308 did not. However, all three different p-AKTs,\nincluding p-Akt Ser473, p-Akt Thr450 and p-Akt Thr308, showed a significantly decreased expression\nin combinatorial inhibition of both mTORC2 and Hsp90. Collectively, it revealed that combinatorial\ninhibition of mTORC2 and Hsp90 could destabilize the Akt signaling.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Our results demonstrated that combinatorial inhibition of mTORC2 and Hsp90 could\nincrease their anti-tumor effect and destabilize the Akt signaling in PC12 cells, suggesting a combinatorial\ninhibition of both mTORC2 and Hsp90 which might be an effective therapeutic strategy for\nmPCC.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568009619666190206120615","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T02:53:37Z","timestamp":1549508017000},"page":"698-706","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combinatorial Inhibition of mTORC2 and Hsp90 Leads to a Distinctly Effective Therapeutic Strategy in Malignant Pheochromocytoma"],"prefix":"10.2174","volume":"19","author":[{"given":"Xiaohua","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Urology, Huashan Hospital Affiliated to Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengbin","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Urology, Huashan Hospital Affiliated to Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","volume":"48","author":"Eisenhofer G.","year":"2012","unstructured":"Eisenhofer G.; Lenders J.W.; Siegert G.; Bornstein S.R.; Friberg P.; Milosevic D.; Mannelli M.; Linehan W.M.; Adams K.; Timmers H.J.; Pacak K.; Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 2012,48(11),1739-1749","journal-title":"Eur J Cancer"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3803\/EnM.2017.32.2.152","volume":"32","author":"Lenders J.W.M.","year":"2017","unstructured":"Lenders J.W.M.; Eisenhofer G.; Update on modern management of pheochromocytoma and paraganglioma. Endocrinol Metab (Seoul) 2017,32(2),152-161","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1055\/s-0029-1220687","volume":"41","author":"Druce M.R.","year":"2009","unstructured":"Druce M.R.; Kaltsas G.A.; Fraenkel M.; Gross D.J.; Grossman A.B.; Novel and evolving therapies in the treatment of malignant phaeochromocytoma: Experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res 2009,41(9),697-702","journal-title":"Horm Metab Res"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","volume":"15","author":"Jimenez C.","year":"2013","unstructured":"Jimenez C.; Rohren E.; Habra M.A.; Rich T.; Jimenez P.; Ayala-Ramirez M.; Baudin E.; Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep 2013,15(4),356-371","journal-title":"Curr Oncol Rep"},{"key":"ref=5","author":"Parenti G.","year":"2012","unstructured":"Parenti G.; Zampetti B.; Rapizzi E.; Ercolino T.; Giache V.; Mannelli M.; Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma\/paraganglioma. J Oncol 2012","journal-title":"J Oncol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","volume":"12","author":"Zoncu R.","year":"2011","unstructured":"Zoncu R.; Efeyan A.; Sabatini D.M.; mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011,12(1),21-35","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=7","first-page":"1623","volume":"38","author":"Kawasaki G.","year":"2018","unstructured":"Kawasaki G.; Naruse T.; Furukawa K.; Umeda M.; mTORC1 and mTORC2 expression levels in oral squamous cell carcinoma: An immunohistochemical and clinicopathological study. Anticancer Res 2018,38(3),1623-1628","journal-title":"Anticancer Res"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1042\/CS20171158","volume":"132","author":"Martelli A.M.","year":"2018","unstructured":"Martelli A.M.; Buontempo F.; McCubrey J.A.; Drug discovery targeting the mTOR pathway. Clin Sci (Lond) 2018,132(5),543-568","journal-title":"Clin Sci (Lond)"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12943-018-0794-0","volume":"17","author":"Jebali A.","year":"2018","unstructured":"Jebali A.; Dumaz N.; The role of RICTOR downstream of receptor tyrosine kinase in cancers. Mol Cancer 2018,17(1),39","journal-title":"Mol Cancer"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/en.2012-1854","volume":"154","author":"Giubellino A.","year":"2013","unstructured":"Giubellino A.; Bullova P.; N\u00f6lting S.; Turkova H.; Powers J.F.; Liu Q.; Guichard S.; Tischler A.S.; Grossman A.B.; Pacak K.; Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology 2013,154(2),646-655","journal-title":"Endocrinology"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/emboj.2008.120","volume":"23, 27","author":"Facchinetti V.","year":"2008","unstructured":"Facchinetti V.; Ouyang W.; Wei H.; Soto N.; Lazorchak A.; Gould C.; Lowry C.; Newton A.C.; Mao Y.; Miao R.Q.; Sessa W.C.; The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 2008,23, 27(14),1932-1943","journal-title":"EMBO J"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1007\/s13277-015-3187-7","volume":"36","author":"Zhang X.","year":"2015","unstructured":"Zhang X.; Wang X.; Xu T.; Zhong S.; Shen Z.; Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma. Tumour Biol 2015,36(7),5273-5281","journal-title":"Tumour Biol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1182\/blood-2011-12-399519","volume":"119","author":"Zhang F.","unstructured":"Zhang F.; Lazorchak A.S.; Liu D.; Chen F.; Su B.; Inhibition of the mTORC2 and chaperone pathways to treat leukemia. Blood, 21 ,119(25),6080-6088","journal-title":"Blood, 21"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3390\/md8041469","volume":"8","author":"Zhang J.Y.","year":"2010","unstructured":"Zhang J.Y.; Tao L.Y.; Liang Y.J.; Chen L.M.; Mi Y.J.; Zheng L.S.; Wang F.; She Z.G.; Lin Y.C.; To K.K.W.; Fu L.W.; Anthracenedione derivatives as anticancer agents isolated from secondary metabolites of the mangrove endophytic fungi. Mar Drugs 2010,8,1469-1481","journal-title":"Mar Drugs"},{"key":"ref=15","first-page":"273","volume":"85","author":"Zhang X.","year":"2015","unstructured":"Zhang X.; Wang X.; Qin L.; Xu T.; Zhu Z.; Zhong S.; Zhang M.; Shen Z.; The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model. Urology 2015,85(1),273","journal-title":"Urology"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"10832","DOI":"10.1073\/pnas.170276797","volume":"97","author":"Sato S.","year":"2000","unstructured":"Sato S.; Fujita N.; Tsuruo T.; Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000,97(20),10832-10837","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1007\/s13277-015-3162-3","volume":"36","author":"Xu Y.","year":"2015","unstructured":"Xu Y.; Zhu Q.; Chen D.; Shen Z.; Wang W.; Ning G.; Zhu Y.; The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model. Tumour Biol 2015,36(7),5103-5108","journal-title":"Tumour Biol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-08-0132","volume":"15","author":"Banerji U.","year":"2009","unstructured":"Banerji U.; Heat shock protein 90 as a drug target: Some like it hot. Clin Cancer Res 2009,15(1),9-14","journal-title":"Clin Cancer Res"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/jclinpath-2012-201134","volume":"66","author":"Xu Y.","year":"2013","unstructured":"Xu Y.; Qi Y.; Rui W.; Zhu Y.; Zhang C.; Zhao J.; Wei Q.; Wu Y.; Shen Z.; Ning G.; Expression and diagnostic relevance of heat shock protein 90 and signal transducer and activator of transcription 3 in malignant pheochromocytoma. J Clin Pathol 2013,66(4),286-290","journal-title":"J Clin Pathol"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.2147\/OTT.S130236","volume":"10","author":"Lian J.","year":"2017","unstructured":"Lian J.; Lin D.; Xie X.; Xu Y.; Xu L.; Meng L.; Zhu Y.; NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo. OncoTargets Ther 2017,10,2219-2226","journal-title":"OncoTargets Ther"},{"key":"ref=21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056083","volume":"8","author":"Giubellino A.","year":"2013","unstructured":"Giubellino A.; Sourbier C.; Lee M.J.; Scroggins B.; Bullova P.; Landau M.; Ying W.; Neckers L.; Trepel J.B.; Pacak K.; Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. PLoS One 2013,8(2)","journal-title":"PLoS One"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/169645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T13:52:35Z","timestamp":1578491555000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/169645\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,12,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009619666190206120615","relation":{},"ISSN":["1568-0096"],"issn-type":[{"type":"print","value":"1568-0096"}],"subject":[],"published":{"date-parts":[[2019,12,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}